Free Trial
NASDAQ:LUNG

Pulmonx (LUNG) Stock Price, News & Analysis

Pulmonx logo
$3.75 +0.31 (+9.01%)
As of 01:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Pulmonx Stock (NASDAQ:LUNG)

Key Stats

Today's Range
$3.39
$3.68
50-Day Range
$3.43
$8.67
52-Week Range
$3.29
$9.74
Volume
163,470 shs
Average Volume
313,820 shs
Market Capitalization
$150.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.07
Consensus Rating
Moderate Buy

Company Overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Pulmonx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

LUNG MarketRank™: 

Pulmonx scored higher than 73% of companies evaluated by MarketBeat, and ranked 423rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pulmonx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pulmonx's stock forecast and price target.
  • Earnings Growth

    Earnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmonx is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmonx is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmonx has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pulmonx's valuation and earnings.
  • Percentage of Shares Shorted

    3.38% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 4.88%, indicating that investor sentiment is improving.
  • Dividend Yield

    Pulmonx does not currently pay a dividend.

  • Dividend Growth

    Pulmonx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.38% of the float of Pulmonx has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmonx has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmonx has recently decreased by 4.88%, indicating that investor sentiment is improving.
  • News Sentiment

    Pulmonx has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Pulmonx this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,128,484.00 in company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Pulmonx is held by insiders.

  • Percentage Held by Institutions

    91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pulmonx's insider trading history.
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

LUNG Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Q1 2025 Pulmonx Corp Earnings Call
See More Headlines

LUNG Stock Analysis - Frequently Asked Questions

Pulmonx's stock was trading at $6.79 at the start of the year. Since then, LUNG stock has decreased by 47.8% and is now trading at $3.5410.
View the best growth stocks for 2025 here
.

Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.01. The company earned $22.54 million during the quarter, compared to analyst estimates of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative trailing twelve-month return on equity of 55.36%.
Read the conference call transcript
.

Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Pulmonx's top institutional investors include Bank of New York Mellon Corp (0.30%), Legato Capital Management LLC (0.22%), Rhumbline Advisers (0.14%) and Vontobel Holding Ltd. (0.03%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, John Mckune, Richard Ferrari and Alissa Hsu Lynch.
View institutional ownership trends
.

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

Today
5/07/2025
Last Earnings
5/07/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LUNG
Fax
N/A
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.07
High Stock Price Target
$17.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+255.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-60,840,000.00
Pretax Margin
-71.12%

Debt

Sales & Book Value

Annual Sales
$83.79 million
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
1.10

Miscellaneous

Free Float
37,237,000
Market Cap
$136.64 million
Optionable
Optionable
Beta
0.65
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:LUNG) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners